Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) issued its quarterly earnings data on Monday. The medical device company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01), FiscalAI reports. The business had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $25.48 million. Xtant Medical had a negative return on equity of 23.45% and a negative net margin of 10.17%.
Xtant Medical Stock Performance
NYSEAMERICAN XTNT opened at $0.27 on Monday. The stock’s 50-day simple moving average is $0.32 and its two-hundred day simple moving average is $0.44. Xtant Medical has a twelve month low of $0.26 and a twelve month high of $0.84. The company has a quick ratio of 1.05, a current ratio of 2.16 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $38.12 million, a price-to-earnings ratio of -3.40 and a beta of -0.19.
Wall Street Analysts Forecast Growth
Separately, Loop Capital set a $1.00 target price on shares of Xtant Medical in a research note on Wednesday, September 2nd. Two equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Xtant Medical currently has a consensus rating of “Buy” and a consensus target price of $1.00.
Get Our Latest Stock Report on Xtant Medical
Xtant Medical Company Profile
Xtant Medical Group, Inc. develops and markets medical products used in spine surgery. Its portfolio includes spinal implant systems and biologic products intended to support bone growth and spinal fusion. The company serves surgeons and healthcare providers, primarily in the United States, and also reaches select international markets through distribution relationships. Its products are used in procedures to treat spinal conditions and support stabilization or fusion. Xtant Medical’s business brings together spinal-device and biologics operations, including products developed through acquisitions.
See Also
- Five stocks we like better than Xtant Medical
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
